Antimicrobial Compounds Targeting Bacterial RNA Polymerase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibacterial agents are inadequate in addressing bacterial infections, with a lack of effective drugs to combat diseases like pneumonia and tuberculosis, and existing inhibitors of bacterial transcription have limited clinical use.
Innovation Solution
Development of compounds that disrupt the σ2.2-β′-CH interaction in bacterial RNA polymerase holoenzyme formation, inhibiting bacterial transcription and proliferation by targeting specific regions crucial for enzyme assembly.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibacterial agents are used, then bacterial infections can be treated, but they are inadequate for resistant bacteria and lack effective drugs for diseases like pneumonia and tuberculosis
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of transcription inhibitors through varying substituents (R1, R2, R3, R4, R5, R6, R7) and core moieties (A, B) to create compounds with enhanced activity against resistant bacteria including MRSA, VRE, and multidrug-resistant tuberculosis and pneumonia pathogens
Solution Approach 2:
The invention achieves universality by designing a broad-spectrum compound series that effectively treats multiple types of bacterial infections including Gram-positive bacteria (MRSA, VRE, streptococci), Gram-negative bacteria, and specific diseases like tuberculosis and pneumonia, making the compounds versatile against diverse bacterial targets
2Reliability
If transcription inhibitors are developed to target bacterial RNA polymerase, then bacterial proliferation can be inhibited, but the clinical use has been limited with only fidaxomicin approved
Solution Approach 1:
The patent applies parameter changes by systematically varying chemical parameters including substituent types (halo, cyano, nitro, amino, hydroxyl, carboxyl groups), linker lengths (m, n, p, q values), and core structures (moieties A and B) to optimize compounds for both efficacy against bacterial RNA polymerase and manufacturability
Solution Approach 2:
The invention uses local quality by introducing specific functional groups and substituents at particular positions in the molecular structure to enhance binding affinity to the β'-clamp helix region of bacterial RNA polymerase while maintaining synthetic feasibility
Data Source
AI summary
Provided herein are compounds useful in the treatment of bacterial infections, pharmaceuticals comprising the same, and methods of use and preparation thereof.